@article{21aff3b9b2be4eb6ae40b81a75e0cacc,
title = "Structural basis of small molecule ATPase inhibition of a human mitotic kinesin motor protein",
abstract = "Kinesin microtubule motor proteins play essential roles in division, including attaching chromosomes to spindles and crosslinking microtubules for spindle assembly. Human kinesin-14 KIFC1 is unique in that cancer cells with amplified centrosomes are dependent on the motor for viable division because of its ability to cluster centrosomes and form bipolar spindles, but it is not required for division in almost all normal cells. Screens for small molecule inhibitors of KIFC1 have yielded several candidates for further development, but obtaining structural data to determine their sites of binding has been difficult. Here we compare a previously unreported KIFC1 crystal structure with new structures of two closely related kinesin-14 proteins, Ncd and KIFC3, to determine the potential binding site of a known KIFC1 ATPase inhibitor, AZ82. We analyze the previously identified kinesin inhibitor binding sites and identify features of AZ82 that favor binding to one of the sites, the α4/α6 site. This selectivity can be explained by unique structural features of the KIFC1 α4/α6 binding site. These features may help improve the drug-like properties of AZ82 and other specific KIFC1 inhibitors.",
author = "Park, {Hee Won} and Zhujun Ma and Haizhong Zhu and Shimin Jiang and Robinson, {Robert C.} and Endow, {Sharyn A.}",
note = "Funding Information: These studies were supported by funds from Duke-NUS Medical School to SAE, A*STAR to RCR, and the Structural Genomics Consortium (SGC) to HWP. We thank Wolfram Tempel of the SGC for his work on the KIFC1 and KIFC3 structures. ZM and SAE thank Sang Hyun Lee for sharing laboratory space and materials, and David M. Virshup for CSCB Programme hospitality. SGC (Charity #1097737) funds were from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute (OGI-055), Innovative Medicines Initiative (EU/EFPIA, ULTRA-DD Grant #115766), Janssen, Merck & Co., Novartis Pharma AG, Ontario Ministry of Research Innovation and Science, Pfizer, S{\~a}o Paulo Research Foundation-FAPESP, Takeda, and the Wellcome Trust. APS use was supported by US-DOE Contract #DE-AC02-06CH11357 to ANL, APS beamline GM/CA by NCI ACB12002 and NIGMS AGM12006, and CHESS beamline F1 by NSF DMR-1332208 and NIGMS GM103485. NSRRC beamline BL13B1 (Hsinchu, Taiwan) was also used for these studies. Publisher Copyright: {\textcopyright} 2017 The Author(s).",
year = "2017",
month = dec,
day = "1",
doi = "10.1038/s41598-017-14754-6",
language = "English",
volume = "7",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",
}